Nuclear Medicine/Radiopharmaceuticals Global Market - Forecast To 2024

Publishing Date : July, 2018
Report Code : HCPH 0099
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Over the past 50 years nuclear medicine field has displayed a strong link between investments in chemistry and development of radionuclides and radio-labeled compounds which has impacted the healthcare practice. Nuclear medicine comprises diagnostic and therapeutic techniques that use radioisotopes for applications like oncology, cardiovascular and neurological disorders to provide information at both molecular and cellular level for probing, tracking tissue function, study disease progression and assessing treatment responses.

The nuclear medicine global market is estimated to reach $9,367.8 million by 2024 growing at mid single digit CAGR. Increased radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) and alpha therapy based targeted cancer treatment is boosting nuclear medicine market growth. In addition, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipments are the opportunities likely to propel the growth of nuclear medicine market.

Nuclear medicinal market is classified based on modality into diagnosis-therapeutics. Diagnostics market held the largest market revenue in 2017 and is expected grow at single digit CAGR due to increase in SPECT and PET procedures. The therapeutics segment is expected to be the fastest growing segment at high double digit CAGR from 2017 to 2024 due to technological advancements in targeted treatment of cancers. Potential new radioisotopes in pipeline and advancement in neurological treatments are the key factors driving the growth of the therapeutics market. Diagnosis by products is segmented into SPECT and PET. SPECT market held the largest market due to increase in TC-99m isotope applications and product approvals. SPECT is segmented based on isotopes into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Samarium (Sm-153), Yttrium (Y-90), Rhenium (Re-186) and others. Technetium (Tc-99m) accounted for largest share in 2017 and is the fastest growing market with projected single digit CAGR growth during 2017 to 2024 due to increase in approvals of Tc-99m based cold kits for different applications. SPECT market by application is segmented into cardiology, pulmonary, oncology, nephrology, neurology, inflammation, thyroid gland, lymphology and others. Cardiology accounted for largest share in 2017 and remains fastest growing market due to increase in number of cardiac imaging cases using Tc-99m.

PET is the fastest growing segment at mid single digit CAGR from 2017 to 2024 due to increase in adoption of cyclotron for production of PET isotopes increasing its availability. The PET isotopes include Fluorodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others. The Fluorodeoxyglucose (18F-FDG) accounted for the largest share in 2017and remains the fastest growing market from 2017 to 2024 due to increase in application related to neurology, bone scan, infection and inflammation. PET by applications is segmented into cardiology, oncology, neurology, inflammation and others. Oncology accounted for largest share in 2017 and is the fastest growing market projected to grow with mid single CAGR from 2017 to 2024 due to increase in patient pool of lung cancer, thyroid cancer and breast cancer.

Therapeutic nuclear medicine market is segmented based on radiation type into alpha radiation, beta radiation and brachytherapy. Alpha radiation accounted largest share in 2017 and is the fastest growing market with projected high double digit CAGR from 2017 to 2024 due to new approval of Ra-223 based cold kits by FDA and other regulatory agencies. Beta radiation therapy by isotopes is further segmented into Y-90, I-131, Lu-177, Sm-153, Re-186, Sr-89, Er-169 and others. I-131 held the largest share and is expected to grow at mid single digit CAGR from 2017 to 2024 due to increased use in treatment of thyroid cancer cases. Lu-177 segment was the fastest growing segment at high single digit CAGR from 2017 to 2024 due to increase in approval of Lu-177 based radiopharmaceuticals for treatment of neuroendocrine tumor. Brachytherapy isotopes are further segmented into I-125, Cs-131, Ir-192, Pd-103 and others. I-125 market accounted the largest share in 2017 and is the fastest growing market with projected CAGR of 3.7% from 2017 to 2024 due to increase in increased use in treatment of lung cancer, prostate cancer, eye related disease (retinoblastoma and eye plaque) and brain cancer. Therapeutic nuclear medicine by application is segmented into prostate cancer, thyroid cancer, liver cancer, gastro-entero-pancreatic-neuroendocrine tumors, metastatic bone cancer, breast cancer and others. Prostate cancer market accounted the largest share in 2017 and is the fastest growing market projected with double digit CAGR growth from 2017 to 2024 due to increase in increased use in treatment of prostate cancer.

Nuclear medicine based on end-user is segmented into hospitals, ambulatory centers, diagnostic centers and others. Hospital accounted the largest share in 2017 and is the fastest growing market projected with CAGR of 7.2% from 2017 to 2024 due to readily availability of cyclotrons for generation of isotope and use of advanced hybrid imaging.

The stable isotope global market is poised to reach $256.9 million by 2024. The Nuclear Medicine market includes stable isotopes which are classified into isotopes and applications. Isotopes considered are carbon (C-13), deuterium (D2), oxygen (O-18), nitrogen (N-15), Sulphur (S-32) and others. Deuterium (D-2) accounted largest share in 2017 and is the fastest growing market with projected low single digit CAGR growth from 2017 to 2024 due to use of deuterium as dietary supplement of deuterium-depleted water which helps to extend survival rate of lung cancer patient via exerting anticancer effect and modification of deuterium leads to development of novel, highly differentiated drugs which have therapeutic applications in diabetic nephropathy, hot flashes, spasticity, neuropathic pain and multiple melanoma. The stable isotope applications market is segmented into diagnostics-therapy, pharmaceutical companies and others. Diagnostics-therapy market commanded the largest market revenue in 2017 and expected to grow at a CAGR of 2.6% due to use in diagnosis and treatment of pancreas, liver and intestine related disorders. The pharmaceuticals is projected to be the fastest growing segment from 2017 to 2024 due to novel developments in utilization of stable isotopes which involve biopolymers, where isotope-labeled species are generated from cells grown on labeled growth media.

Geographical wise, North America is the largest market, with a significant share followed by Europe, Asia-Pacific and Rest of the World. North American region commanded the largest revenue market and expected to grow at mid single digit CAGR. Growing use of SPECT and PET scans, technological advancements in equipment, increased utilization of fusion imaging, alpha radio immunotherapy based targeted cancer treatment and complete availability of radiopharmaceutical has led the market growth in this region. However, Asia-Pacific region is expected to grow at a high single digit CAGR from 2017 to 2024 due to increased public awareness and increase in application.

The nuclear medicine global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring small companies for product expansion. Some of the key players of the nuclear medicine market are Curium Pharma (France), Bayer AG (Germany), GE Company (U.S.), Cardinal Health (U.S.), Jubilant Life science (India), Lantheus Medical Imaging (U.S.), Novartis International AG (Advanced accelerator) (Switzerland), South African Nuclear Energy Corporation (NTP Radioisotopes SOC Ltd) (South Africa), Siemens AG (Germany) and Fujifilm Holding Corporation (Japan).

The report provides an in depth market analysis of the above mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific 
  • Rest of the World (RoW)
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKE AWAYS
    • 2.2     REPORT scope
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET CRACKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.7     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.8     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASED APPLICATIONS OF RADIOPHARMACEUTICALS
        • 3.3.1.2     RISE IN PUBLIC AWARENESS
        • 3.3.1.3     USAGE OF HYBRID IMAGING
        • 3.3.1.4     TECHNOLOGICAL ADVANCEMENTS
        • 3.3.1.5     INCREASING NEEDS IN EMERGING MARKETS
        • 3.3.1.6     PRODUCTION OF RADIOPHARMACEUTICALS FROM CYCLOTRONS
        • 3.3.1.7     EFFICIENT DIAGNOSIS AND TREATMENTS
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS
        • 3.3.2.2     HIGH COST AND SUPPLY SHORTAGE OF ISOTOPES
        • 3.3.2.3     RADIO TOXICITY
        • 3.3.2.4     SHORTAGE OF QUALIFIED TECHNICIANS
        • 3.3.2.5     REGULATORY ISSUES
        • 3.3.2.6     THREAT FROM TRADITIONAL/ALTERNATIVE DIAGNOSTIC PROCEDURES
        • 3.3.2.7     HUGE CAPITAL INVESTMENT
    • 3.4     PROBLEM AREAS
      • 3.4.1     CLOSURE OF REACTORS
    • 3.5     WINNING IMPERATIVES
      • 3.5.1     AVAILABILITY OF TECHNETIUM
    • 3.6     REGULATORY GUIDELINES
      • 3.6.1     UNITED STATES
      • 3.6.2     EUROPE
      • 3.6.3     JAPAN
      • 3.6.4     INDIA
      • 3.6.5     CHINA
      • 3.6.6     SOUTH KOREA
    • 3.7     REIMBURSEMENT SCENARIO and CHALLENGES
    • 3.8     CLINICAL TRIALS
    • 3.9     PATENT TRENDS
    • 3.10     SUPPLY CHAIN ANALYSIS
      • 3.10.1     REACTORS
      • 3.10.2     PROCESSING FACILITY
      • 3.10.3     GENERATORS MANUFACTURING UNITS
      • 3.10.4     HOSPITALS AND CENTRAL RADIO PHARMACIES
    • 3.11     LIST OF POTENTIAL NEW REACTORS
    • 3.12     LIST OF FDA APROVED RADIOPHARMACEUTICALS
    • 3.13     PORTER'S FIVE FORCE ANALYSIS
      • 3.13.1     THREAT OF NEW ENTRANTS
      • 3.13.2     THREAT OF SUBSTITUTES
      • 3.13.3     BARGAINING POWER OF SUPPLIERS
      • 3.13.4     BARGAINING POWER OF BUYERS
      • 3.13.5     COMPETITIVE RIVALRY
    • 3.14     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.14.1     NUCLEAR MEDICINE MARKET
      • 3.14.2     SPECT MARKET
      • 3.14.3     PET MARKET
      • 3.14.4     TC-99 MARKET
  • 4     NUCLEAR MEDICINE GLOBAL MARKET, BY MODALITY
    • 4.1     INTRODUCTION
    • 4.2     DIAGNOSTICS
      • 4.2.1     RADIOPHARMACEUTICALS FOR DIAGNOSIS, BY ISOTOPES
        • 4.2.1.1     SPECT, BY ISOTOPES
          • 4.2.1.1.1     TECHNETIUM (Tc-99M)
          • 4.2.1.1.2     THALLIUM (Tl-201)
          • 4.2.1.1.3     GALLIUM (Ga-67)
          • 4.2.1.1.4     IODINE (I-123)
          • 4.2.1.1.5     SAMARIUM (Sm-153)
          • 4.2.1.1.6     YTTRIUM (Y-90)
          • 4.2.1.1.7     RHENIUM (Re-186)
          • 4.2.1.1.8     OTHERS
        • 4.2.1.2     PET, BY ISOTOPES
          • 4.2.1.2.1     FLUORODEOXYGLUCOSE (18F-FDG)
          • 4.2.1.2.2     GALLIUM (Ga-68)
          • 4.2.1.2.3     RUBIDIUM (Rb-82)
          • 4.2.1.2.4     OTHERS
      • 4.2.2     NUCLEAR MEDICINE FOR DIAGNOSIS, BY APPLICATION
        • 4.2.2.1     SPECT BY APPLICATION
          • 4.2.2.1.1     CARDIOLOGY
          • 4.2.2.1.2     PULMONARY
          • 4.2.2.1.3     ONCOLOGY
          • 4.2.2.1.4     NEPHROLOGY
          • 4.2.2.1.5     NEUROLOGY
          • 4.2.2.1.6     INFLAMMATION
          • 4.2.2.1.7     THYROID GLANDS
          • 4.2.2.1.8     LYMPHOLOGY
          • 4.2.2.1.9     OTHERS
        • 4.2.2.2     PET BY APPLICATION
          • 4.2.2.2.1     ONCOLOGY
          • 4.2.2.2.2     NEUROLOGY
          • 4.2.2.2.3     CARDIOLOGY
          • 4.2.2.2.4     INFLAMMATION
          • 4.2.2.2.5     OTHERS
    • 4.3     THERAPEUTICS
      • 4.3.1     NUCLEAR MEDICINE FOR THERAPEUTICS, BY RADIATION TYPE
        • 4.3.1.1     BETA RADIATION THERAPY
          • 4.3.1.1.1     YTTRIUM (Y-90)
          • 4.3.1.1.2     IODINE (I-131)
          • 4.3.1.1.3     LUTETIUM (LU-177)
          • 4.3.1.1.4     SAMARIUM (SM-153)
          • 4.3.1.1.5     RHENIUM (Re-186)
          • 4.3.1.1.6     STRONTIUM (Sr-89)
          • 4.3.1.1.7     ERBIUM (Er-169)
          • 4.3.1.1.8     OTHERS
        • 4.3.1.2     ALPHA RADIATION THERAPY, BY ISOTOPES
        • 4.3.1.3     BRACHYTHERAPY, BY ISOTOPES
          • 4.3.1.3.1     IODINE (I-125)
          • 4.3.1.3.2     CESIUM (Cs-131)
          • 4.3.1.3.3     IRIDIUM (Ir-192)
          • 4.3.1.3.4     PALLADIUM (Pd-103)
          • 4.3.1.3.5     OTHERS
      • 4.3.2     NUCLEAR MEDICINE THERAPEUTICS, BY APPLICATION
        • 4.3.2.1     PROSTATE CANCER
        • 4.3.2.2     THYROID CANCER
        • 4.3.2.3     LIVER CANCER
        • 4.3.2.4     GEP-NET THERAPEUTICS
        • 4.3.2.5     METASTATIC BONE CANCER THERAPEUTICS
        • 4.3.2.6     BREAST CANCER THERAPEUTICS
        • 4.3.2.7     OTHER THERAPEUTIC APPLICATIONS
  • 5     NUCLEAR MEDICINE GLOBAL MARKET, BY END-USERS
    • 5.1     INTRODUCTION
    • 5.2     HOSPITAL
    • 5.3     AMBULATORY CENTERS
    • 5.4     DIAGNOSTIC CENTERS
    • 5.5     OTHER END-USERS
  • 6     STABLE ISOTOPES
    • 6.1     INTRODUCTION
    • 6.2     MARKET ANALYSIS
      • 6.2.1     FACTORS INFLUENCING MARKET
      • 6.2.2     DRIVERS AND OPPORTUNITIES
        • 6.2.2.1     INCREASE IN RESEARCH ACTIVITIES (PHARMACEUTICALS AND BIOTECHNOLOGY SECTORS)
        • 6.2.2.2     INCREASING APPLICATIONS
      • 6.2.3     RESTRAINTS AND THREATS
        • 6.2.3.1     HIGH COST OF STABLE ISOTOPES
        • 6.2.3.2     STABLE ISOTOPES-SIDE EFFECTS AND SAFETY ISSUES
        • 6.2.3.3     STRINGENT REGULATIONS FOR MANUFACTURING AND USE OF STABLE ISOTOPES
    • 6.3     STABLE ISOTOPES MARKET, BY ISOTOPE
      • 6.3.1     CARBON (C-13)
      • 6.3.2     DEUTERIUM (D2)
      • 6.3.3     OXYGEN (O-18)
      • 6.3.4     NITROGEN (N-15)
      • 6.3.5     SULPHUR (S-32)
      • 6.3.6     OTHERS
    • 6.4     STABLE ISOTOPES MARKET, BY APPLICATION
      • 6.4.1     INTRODUCTION
      • 6.4.2     DIAGNOSTICS AND THERAPY
      • 6.4.3     PHARMACEUTICALS
      • 6.4.4     OTHERS
    • 6.5     STABLE ISOTOPES MARKET, BY GEOGRAPHY
      • 6.5.1     INTRODUCTION
      • 6.5.2     NORTH AMERICA
      • 6.5.3     EUROPE
      • 6.5.4     ASIA-PACIFIC
      • 6.5.5     REST OF THE WORLD
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     OTHERS
    • 7.3     EUROPE
      • 7.3.1     GERMANY
      • 7.3.2     FRANCE
      • 7.3.3     ITALY
      • 7.3.4     OTHERS
    • 7.4     ASIA-PACIFIC
      • 7.4.1     JAPAN
      • 7.4.2     CHINA
      • 7.4.3     AUSTRALIA
      • 7.4.4     OTHERS
    • 7.5     REST OF THE WORLD
      • 7.5.1     BRAZIL
      • 7.5.2     REST OF LATIN AMERICA
      • 7.5.3     MIDDLE EAST AND SOUTH AFRICA
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     APPROVALS AND AGREEMENTS
    • 8.3     ACQUISITION, EXPANSION AND COLLABORATION
    • 8.4     OTHERS DEVELOPMENTS
  • 9     MAJOR PLAYER PROFILES
    • 9.1     ADVANCE ACCELERATOR APPLICATIONS SA (NOVARTIS)
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANIZATION (ANSTO)
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     BAYER GROUP
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     CARDINAL HEALTH INC.
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     CURIUM PHARMA
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS SRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     FUJIFILM HOLDINGS CORPORATION
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS SRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     GE COMPANY (GE HEALTHCARE)
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS SRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     JUBILANT LIFESCIENCE
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS SRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     LANTHEUS MEDICAL IMAGING INC.
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.10     SOTERA HEALTH LLC (NORDION INC)
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS
    • 9.11     SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NECSA) (NTP RADIOISOTOPES SOC LTD)
      • 9.11.1     OVERVIEW
      • 9.11.2     FINANCIALS
      • 9.11.3     PRODUCT PORTFOLIO
      • 9.11.4     KEY DEVELOPMENTS
      • 9.11.5     BUSINESS STRATEGY
      • 9.11.6     SWOT ANALYSIS
    • 9.12     SIEMENS AG
      • 9.12.1     OVERVIEW
      • 9.12.2     FINANCIALS
      • 9.12.3     PRODUCT PORTFOLIO
      • 9.12.4     KEY DEVELOPMENTS
      • 9.12.5     BUSINESS STRATEGY
      • 9.12.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 2     RADIOPHARMACUTICALS THAT WILL CONTINUE TO RECEIVE PASS THROUGH STATUS
      • TABLE 3     REIMBURSEMENT RATES FOR RADIOPHARMACEUTICALS AND DIAGNOSTIC IMAGING TECHNIQUES
      • TABLE 4     TECHNETIUM (TC-99M) REACTORS
      • TABLE 5     NEW POTENTIAL REACTORS
      • TABLE 6     FDA APPROVED RADIOPHARMACEUTICALS
      • TABLE 7     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY MODALITY, (2016-2024) ($MN)
      • TABLE 8     NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCTS, (2016-2024) ($MN)
      • TABLE 9     NUCLEAR MEDICINE DIAGNOSTIC GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 10     NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 11     NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 12     TECHNETIUM (TC-99M) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 13     THALLIUM (TL-201) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 14     GALLIUM (GA-67) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 15     IODINE (I-123) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 16     SAMARIUM (SM-153) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 17     YTTRIUM (Y-90) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 18     RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 19     OTHER ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 20     NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY ISOTOPES, (2016-2024) ($MN)
      • TABLE 21     NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 22     FLUORODEOXYGLUCOSE (18F-FDG) GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 23     GALLIUM (GA-68) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 24     RUBIDIUM (RB-82) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 25     OTHER PET ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 26     NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 27     CARDIOLOGY GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 28     PULMONARY GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 29     ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 30     NEPHROLOGY GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 31     NEUROLOGY GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 32     INFLAMMATION GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 33     THYROID GLANDS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 34     LYMPHOLOGY SPECT GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 35     OTHER APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 36     NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 37     ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 38     NEUROLOGY GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 39     CARDIOLOGY GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 40     INFLAMMATION GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 41     OTHERS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 42     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BY RADIATION TYPE, (2016-2024) ($MN)
      • TABLE 43     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 44     BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BY ISOTOPES, (2016-2024) ($MN)
      • TABLE 45     BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 46     YTTRIUM (Y-90) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 47     IODINE(I-131) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 48     LUTETIUM (LU-177) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 49     SAMARIUM (SM-153) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 50     RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 51     STRONTIUM (SR-89) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 52     ERBIUM (ER-169) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 53     OTHER ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 54     ALPHA RADIATION THERAPY GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 55     BRACHYTHERAPY GLOBAL MARKET REVENUE, BY ISOTOPES, (2016-2024) ($MN)
      • TABLE 56     BRACHYTHERAPY GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 57     IODINE (I-125) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 58     CESIUM (CS-131) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 59     IRIDIUM (IR-192) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 60     PALLADIUM (PD-103) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 61     OTHER ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 62     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 63     PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 64     THYROID CANCER GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 65     LIVER CANCER GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 66     GEP-NET GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 67     METASTATIC BONE CANCER GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 68     BREAST CANCER GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 69     OTHER THERAPEUTIC APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 70     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY END-USERS, (2016-2024) ($MN)
      • TABLE 71     HOSPITAL GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 72     AMBULATORY CENTERS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 73     DIAGNOSTIC CENTRES END-USER GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 74     OTHER END-USER GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 75     STABLE ISOTOPES GLOBAL MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 76     STABLE ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 77     CARBON (C-13) GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 78     DEUTERIUM (D2) GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 79     OXYGEN (O-18) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 80     NITROGEN (N-15) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 81     SULPHUR (S-32) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 82     OTHER STABLE ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 83     STABLE ISOTOPES GLOBAL MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 84     DIAGNOSTICS-THERAPY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 85     PHARMACEUTICALS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 86     OTHERS GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 87     STABLE ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 88     NORTH AMERICA STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 89     NORTH AMERICA STABLE ISOTOPES MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 90     EUROPE STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 91     EUROPE STABLE ISOTOPES MARKET REVENUE, BY APPLICATION, (2016 -2024) ($MN)
      • TABLE 92     ASIA-PACIFIC STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 93     ASIA-PACIFIC STABLE ISOTOPES MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 94     REST OF THE WORLD STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 95     REST OF THE WORLD STABLE ISOTOPES MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 96     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY REGION, (2016-2024) ($MN)
      • TABLE 97     NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2016-2024) ($MN)
      • TABLE 98     NORTH AMERICA NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2016-2024) ($MN)
      • TABLE 99     NORTH AMERICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 100     NORTH AMERICA NUCLEAR MEDICINE PET MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 101     NORTH AMERICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 102     NORTH AMERICA NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 103     NORTH AMERICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY RADIATION TYPE, (2016-2024) ($MN)
      • TABLE 104     NORTH AMERICA NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 105     NORTH AMERICA NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 106     NORTH AMERICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 107     NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BY END-USERS, (2016-2024) ($MN)
      • TABLE 108     NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN)
      • TABLE 109     EUROPE NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2016-2024) ($MN)
      • TABLE 110     EUROPE NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2016-2024) ($MN)
      • TABLE 111     EUROPE NUCLEAR MEDICINE SPECT MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 112     EUROPE NUCLEAR MEDICINE PET MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 113     EUROPE NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 114     EUROPE NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 115     EUROPE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY RADIATION TYPE, (2016-2024) ($MN)
      • TABLE 116     EUROPE NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 117     EUROPE NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 118     EUROPE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 119     EUROPE NUCLEAR MEDICINE MARKET REVENUE, BY END-USERS, (2016-2024) ($MN)
      • TABLE 120     EUROPE NUCLEAR MEDICINE MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN)
      • TABLE 121     ASIA-PACIFIC NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2016-2024) ($MN)
      • TABLE 122     ASIA-PACIFIC NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2016-2027) ($MN)
      • TABLE 123     ASIA-PACIFIC NUCLEAR MEDICINE SPECT MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 124     ASIA-PACIFIC NUCLEAR MEDICINE PET MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 125     ASIA-PACIFIC NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 126     ASIA-PACIFIC NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 127     ASIA-PACIFIC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY RADIATION TYPE, (2016-2024) ($MN)
      • TABLE 128     ASIA-PACIFIC NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 129     ASIA-PACIFIC NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 130     ASIA-PACIFIC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 131     ASIA-PACIFIC NUCLEAR MEDICINE MARKET REVENUE, BY END-USERS, (2016-2024) ($MN)
      • TABLE 132     ASIA-PACIFIC NUCLEAR MEDICINE MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN)
      • TABLE 133     REST OF THE WORLD NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2016-2024) ($MN)
      • TABLE 134     REST OF THE WORLD NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2016-2024) ($MN)
      • TABLE 135     REST OF THE WORLD NUCLEAR MEDICINE SPECT MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 136     REST OF THE WORLD NUCLEAR MEDICINE PET MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 137     REST OF THE WORLD NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 138     REST OF THE WORLD NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 139     REST OF THE WORLD NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY RADIATION TYPE, (2016-2024) ($MN)
      • TABLE 140     REST OF THE WORLD NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 141     REST OF THE WORLD NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE, BY ISOTOPE, (2016-2024) ($MN)
      • TABLE 142     REST OF THE WORLD NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • TABLE 143     REST OF THE WORLD NUCLEAR MEDICINE MARKET REVENUE, BY END-USERS, (2016-2024) ($MN)
      • TABLE 144     ROW NUCLEAR MEDICINE MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN)
      • TABLE 145     APPROVALS AND AGREEMENTS (2016-2018)
      • TABLE 146     ACQUISITION, EXPANSION AND COLLABORATION, (2016-2018)
      • TABLE 147     OTHER DEVELOPMENTS (2016-2018)
      • TABLE 148     ADVANCE ACCELERATOR APPLICATIONS SA: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
      • TABLE 149     ADVANCE ACCELERATOR APPLICATIONS SA: TOTAL REVENUE, BY SEGMENTS (2015-2017) ($MN)
      • TABLE 150     ADVANCE ACCELERATOR APPLICATIONS SA: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
      • TABLE 151     AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANIZATION: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
      • TABLE 152     OVERVIEW: BAYER GROUP
      • TABLE 153     BAYER GROUP: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 154     BAYER GROUP: TOTAL REVENUE, BY SEGMENTS (2015-2017) ($MN)
      • TABLE 155     BAYER GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 156     CARDINAL HEALTH, INC.: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
      • TABLE 157     CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENTS, (2016-2018) ($MN)
      • TABLE 158     CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 159     OVERVIEW: FUJIFILM HOLDING CORPORATION
      • TABLE 160     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2016 – 2018) ($MN)
      • TABLE 161     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
      • TABLE 162     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2016 – 2018) ($MN)
      • TABLE 163     OVERVIEW: GE COMPANY
      • TABLE 164     GE COMPANY: TOTAL REVENUE AND R&D EXPENSES (2015 – 2017) ($MN)
      • TABLE 165     GE COMPANY: TOTAL REVENUE, BY SEGMENTS (2015-2017) ($MN)
      • TABLE 166     GE COMPANY: TOTAL REVENUE, BY GEOGRAPHY (2015 – 2017) ($MN)
      • TABLE 167     JUBILANT LIFESCIENCE: TOTAL REVENUE AND R&D EXPENSES (2015 – 2017) ($MN)
      • TABLE 168     JUBILANT LIFESCIENCE: TOTAL REVENUE, BY SEGMENTS (2015-2017) ($MN)
      • TABLE 169     JUBILANT LIFESCIENCE: PHARMACEUTICAL TOTAL REVENUE, BY SEGMENTS (2015-2017) ($MN)
      • TABLE 170     JUBILANT LIFESCIENCE: SPCEIALTY PHARMACEUTICAL INJECTABLES TOTAL REVENUE, BY SEGMENTS (2015-2017) ($MN)
      • TABLE 171     JUBILANT LIFESCIENCE: TOTAL REVENUE, BY GEOGRAPHY (2015 – 2017) ($BN)
      • TABLE 172     OVERVIEW: LANTHEUS MEDICAL IMAGING INC.
      • TABLE 173     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 174     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY PRODUCTS (2015-2017) ($MN)
      • TABLE 175     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
      • TABLE 176     SIEMENS AG: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 177     SIEMENS AG: TOTAL REVENUE, BY SEGMENT, (2015-2017) ($MN)
      • TABLE 178     SIEMENS AG : TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)

      LIST OF FIGURES

      • FIGURE 1     NUCLEAR MEDICINE GLOBAL MARKET SHARE AND REVENUE, BY REGION, (2016-2024) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: NUCLEAR MEDICINE GLOBAL MARKET
      • FIGURE 3     NUCLEAR MEDICINE GLOBALMARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     NUCLEAR MEDICINE GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     NUCLEAR MEDICINE GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
      • FIGURE 6     NUCLEAR MEDICINE GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 7     STABLE ISOTOPES GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 8     MARKET DYNAMICS
      • FIGURE 9     NUCLEAR MEDICINE GLOBAL MARKET: PCT PATENT FILING BY MAJOR PLAYERS (2013-2018)
      • FIGURE 10     TECHNETIUM -99: SUPPLY CHAIN ANALYSIS
      • FIGURE 11     NUCLEAR MEDICINE MARKET: PORTER’S ANALYSIS
      • FIGURE 12     NUCLEAR MEDICINE GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2017 (%)
      • FIGURE 13     SPECT MARKET: MAJOR PLAYER ANALYSIS (2017) (%)
      • FIGURE 14     PET MARKET: MAJOR PLAYER ANALYSIS (2017) (%)
      • FIGURE 15     TC -99: MAJOR PLAYER ANALYSIS (2017) (%)
      • FIGURE 16     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY MODALITY, (2016-2024) ($MN)
      • FIGURE 17     NUCLEAR MEDICINE ISOTOPES, BY MODALITY
      • FIGURE 18     NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCTS, (2016-2024) ($MN)
      • FIGURE 19     NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 20     NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY ISOTOPE, (2017 V/S 2024) ($MN)
      • FIGURE 21     NUCLEAR MEDICINE SPECT GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 22     NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY ISOTOPE, (2017 V/S 2024) ($MN)
      • FIGURE 23     NUCLEAR MEDICINE PET GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 24     FLUORODEOXYGLUCOSE (18F-FDG) GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 25     GALLIUM (GA-68) ISOTOPE GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 26     RUBIDIUM (RB-82) ISOTOPE GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 27     NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 28     NUCLEAR MEDICINE SPECT ISOTOPES, BY APPLICATION
      • FIGURE 29     INFLAMMATION GLOBAL MARKET SHARE, BY APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 30     THYROID GLAND GLOBAL MARKET SHARE, BY APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 31     NUCLEAR MEDICINE PET GLOBAL MARKET SHARE, BY APPLICATION, (2017) (%)
      • FIGURE 32     CARDIOLOGY GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 33     NUCLEAR MEDICINE PET ISOTOPES, BY APPLICATION
      • FIGURE 34     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BY RADIATION TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 35     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 36     THERAPEUTIC ISOTOPES, BY APPLICATION
      • FIGURE 37     BETA RADIATION THERAPY GLOBAL MARKET SHARE, BY ISOTOPE, (2017) (%)
      • FIGURE 38     BETA RADIATION THERAPY GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 39     IODINE (I-131) ISOTOPE GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 40     ALPHA RADIATION THERAPY GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 41     NUCLEAR MEDICINE BRACHYTHERAPY GLOBAL MARKET SHARE, BY ISOTOPE, (2017) (%)
      • FIGURE 42     BRACHYTHERAPY GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 43     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 44     THYROID CANCER GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 45     NUCLEAR MEDICINE GLOBAL MARKET SHARE, BY END-USERS, (2017) (%)
      • FIGURE 46     DIAGNOSTIC CENTER GLOBAL MARKET SHARE, BY REGION, (2017 V/S 2024) (%)
      • FIGURE 47     STABLE ISOTOPES GLOBAL MARKET SHARE, BY ISOTOPE, (2017) (%)
      • FIGURE 48     STABLE ISOTOPES MARKET: MARKET DYNAMICS
      • FIGURE 49     STABLE ISOTOPES GLOBAL MARKET REVENUE, BY APPLICATION, (2016-2024) ($MN)
      • FIGURE 50     STABLE ISOTOPE GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN), CAGR (%)
      • FIGURE 51     NORTH AMERICA STABLE ISOTOPES MARKET SHARE, BY ISOTOPES, (2017) (%)
      • FIGURE 52     NORTH AMERICA STABLE ISOTOPES MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 53     EUROPE STABLE ISOTOPES MARKET SHARE, BY ISOTOPES, (2017) (%)
      • FIGURE 54     EUROPE STABLE ISOTOPES MARKET REVENUE, BY APPLICATION, (2017 V/S) ($MN)
      • FIGURE 55     ASIA-PACIFIC STABLE ISOTOPES MARKET SHARE, BY ISOTOPES, (2017) (%)
      • FIGURE 56     ASIA-PACIFIC STABLE ISOTOPES MARKET REVENUE, BY ISOTOPES, (2017 V/S 2024) ($MN)
      • FIGURE 57     REST OF THE WORLD STABLE ISOTOPES MARKET SHARE, BY ISOTOPES, (2017) (%)
      • FIGURE 58     REST OF THE WORLD STABLE ISOTOPES MARKET REVENUE, BY APPLICATON, (2017 V/S) ($MN)
      • FIGURE 59     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN), CAGR (%)
      • FIGURE 60     NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2017) ($MN)
      • FIGURE 61     NORTH AMERICA SPECT MARKET SHARE, BY ISOTOPE, (2017 V/S 2024) (%)
      • FIGURE 62     NORTH AMERICA PET MARKET SHARE, BY ISOTOPES, (2017 V/S 2024) (%)
      • FIGURE 63     NORTH AMERICA SPECT MARKET SHARE, BY APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 64     NORTH AMERICA PET MARKET SHARE, BY APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 65     NORTH AMERICA THERAPEUTIC MARKET REVENUE, BY RADIATION TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 66     NORTH AMERICA BETA RADIATION THERAPY MARKET SHARE, BY ISOTOPE, (2017 V/S 2024) (%)
      • FIGURE 67     NORTH AMERICA BRACHYTHERAPY MARKET SHARE,BY ISOTOPE, (2017 V/S 2024) (%)
      • FIGURE 68     NORTH AMERICA NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BY APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 69     NORTH AMERICA NUCLEAR MEDICINE SHARE, BY END-USER, (2017) (%)
      • FIGURE 70     NORTH AMERICA NUCLEAR MEDICINE MARKET SHARE, BY COUNTRY, (2017 V/S 2024) (%)
      • FIGURE 71     U.S. NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNSOTIC MARKET REVENUE, BY PRODUCT, (2017) ($MN)
      • FIGURE 72     U.S. NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 73     U.S. PET MARKET REVENUE, BY APPLICATION AND THERAPEUTIC MARKET REVENUE BY RADIATION TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 74     U.S. NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE BY APPLICATION AND NUCLEAR MEDICINE MARKET REVENUE BY END-USER, (2017 V/S 2024) ($MN)
      • FIGURE 75     OTHER NORTH AMERICAN COUNTRIES NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE, BY PRODUCT, (2017) ($MN)
      • FIGURE 76     OTHER NORTH AMERICAN COUNTRIES NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 77     OTHER NORTH AMERICAN COUNTRIES NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION AND THERAPEUTIC MARKET REVENUE BY RADIATION TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 78     OTHER NORTH AMERICAN COUNTRIES NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE BY APPLICATION AND NUCLEAR MEDICINE BY END-USER, (2017 V/S 2024) ($MN)
      • FIGURE 79     EUROPE NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2017) ($MN)
      • FIGURE 80     EUROPE SPECT MARKET SHARE, BY ISOTOPE, (2017 V/S 2024) (%)
      • FIGURE 81     EUROPE PET MARKET SHARE, BY ISOTOPES, (2017 V/S 2024) (%)
      • FIGURE 82     EUROPE SPECT MARKET SHARE, BY APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 83     EUROPE PET MARKET SHARE, BY APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 84     EUROPE THERAPEUTIC MARKET REVENUE, BY RADIATION TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 85     EUROPE BETA RADIATION THERAPY MARKET SHARE, BY ISOTOPE, (2017 V/S 2024) (%)
      • FIGURE 86     EUROPE BRACHYTHERAPY MARKET SHARE, BY ISOTOPE, (2017 V/S 2024) (%)
      • FIGURE 87     EUROPE NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BY APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 88     EUROPE NUCLEAR MEDICINE SHARE, BY END-USER, (2017) (%)
      • FIGURE 89     EUROPE NUCLEAR MEDICINE SHARE, BY COUNTRY, (2017 V/S 2024) (%)
      • FIGURE 90     GERMANY NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE, BY PRODUCT, (2017) ($MN)
      • FIGURE 91     GERMANY NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 92     GERMANY PET MARKET REVENUE, BY APPLICATION AND THERAPEUTIC MARKET REVENUE BY RADIATION TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 93     GERMANY NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE BY APPLICATION AND NUCLEAR MEDICINE MARKET REVENUE BY END-USER, (2017 V/S 2024) ($MN)
      • FIGURE 94     FRANCE NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2017) ($MN)
      • FIGURE 95     FRANCE NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 96     FRANCE PET MARKET REVENUE BY APPLICATION AND THERAPEUTIC MARKET REVENUE BY RADIATION TYPE (2017 V/S 2024) ($MN)
      • FIGURE 97     FRANCE NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE BY APPLICATION AND NUCLEAR MEDICINE MARKET REVENUE BY END-USER, (2017 V/S 2024) ($MN)
      • FIGURE 98     ITALY NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2017) ($MN)
      • FIGURE 99     ITALY NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 100     ITALY PET MARKET REVENUE, BY APPLICATION AND THERAPEUTIC MARKET REVENUE BY RADIATION TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 101     ITALY NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE BY APPLICATION AND NUCLEAR MEDICINE MARKET REVENUE BY END-USER, (2017 V/S 2024) ($MN)
      • FIGURE 102     OTHER EUROPEAN COUNTRIES NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2017) ($MN)
      • FIGURE 103     OTHER EUROPEAN COUNTRIES NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 104     OTHER EUROPEAN COUNTRIES PET MARKET REVENUE BY APPLICATION AND THERAPEUTIC MARKET REVENUE BY RADIATION TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 105     OTHER EUROPEAN COUNTRIES NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE BY APPLICATION AND NUCLEAR MEDICINE MARKET REVENUE BY END-USER, (2017 V/S 2024) ($MN)
      • FIGURE 106     ASIA-PACIFIC NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2017) ($MN)
      • FIGURE 107     ASIA-PACIFIC SPECT MARKET SHARE, BY ISOTOPE, (2017 V/S 2024) (%)
      • FIGURE 108     ASIA-PACIFIC PET MARKET SHARE, BY ISOTOPES, (2017 V/S 2024) (%)
      • FIGURE 109     ASIA-PACIFIC SPECT MARKET SHARE, BY APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 110     ASIA-PACIFIC PET MARKET SHARE, BY APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 111     ASIA-PACIFIC THERAPEUTIC MARKET SHARE, BY RADIATION TYPE, (2017 V/S 2024) (%)
      • FIGURE 112     ASIA-PACIFIC BETA RADIATION THERAPY MARKET SHARE, BY ISOTOPE, (2017 V/S 2024) (%)
      • FIGURE 113     ASIA-PACIFIC BRACHYTHERAPY MARKET SHARE, BY ISOTOPE, (2017 V/S 2024) (%)
      • FIGURE 114     ASIA-PACIFIC NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BY APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 115     ASIA-PACIFIC NUCLEAR MEDICINE MARKET SHARE, BY END-USER, (2017) (%)
      • FIGURE 116     ASIA-PACIFIC NUCLEAR MEDICINE MARKET SHARE, BY COUNTRY, (2017 V/S 2024) (%)
      • FIGURE 117     JAPAN NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2017) ($MN)
      • FIGURE 118     JAPAN NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 119     JAPAN PET MARKET REVENUE, BY APPLICATION AND THERAPEUTIC MARKET REVENUE BY RADIATION TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 120     JAPAN NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE BY APPLICATION AND NUCLEAR MEDICINE MARKET REVENUE BY END-USER, (2017 V/S 2024) ($MN)
      • FIGURE 121     CHINA NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2017) ($MN)
      • FIGURE 122     CHINA NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 123     CHINA PET MARKET REVENUE BY APPLICATION AND THERAPEUTIC MARKET REVENUE BY RADIATION TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 124     CHINA NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE BY APPLICATION AND NUCLEAR MEDICINE MARKET REVENUE BY END-USER, (2017 V/S 2024) ($MN)
      • FIGURE 125     AUSTRALIA NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2017) ($MN)
      • FIGURE 126     AUSTRALIA NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 127     AUSTRALIA PET MARKET REVENUE BY APPLICATION AND THERAPEUTIC MARKET REVENUE BY RADIATION TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 128     AUSTRALIA NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BY APPLICATION AND NUCLEAR MEDICINE MARKET REVENUE, BY END-USER, (2017 V/S 2024) ($MN)
      • FIGURE 129     OTHER ASIA-PACIFIC COUNTRIES NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2017) ($MN)
      • FIGURE 130     OTHER ASIA-PACIFIC COUNTRIES NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 131     OTHER ASIA-PACIFCI COUNTIRES PET MARKET REVENUE, BY APPLICATION AND THERAPEUTIC MARKET REVENUE BY RADIATION TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 132     OTHER ASIA-PACIFIC COUNTRIES NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE BY APPLICATION AND NUCLEAR MEDICINE MARKET REVENUE BY END-USER, (2017 V/S 2024) ($MN)
      • FIGURE 133     REST OF THE WORLD NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2017) ($MN)
      • FIGURE 134     REST OF THE WORLD SPECT MARKET SHARE, BY ISOTOPE, (2017 V/S 2024) (%)
      • FIGURE 135     REST OF THE WORLD PET MARKET SHARE, BY ISOTOPES, (2017 V/S 2024) (%)
      • FIGURE 136     REST OF THE WORLD SPECT MARKET SHARE, BY APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 137     REST OF THE WORLD PET MARKET SHARE, BY APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 138     REST OF THE WORLD THERAPEUTIC MARKET SHARE, BY RADIATION TYPE, (2017 V/S 2024) (%)
      • FIGURE 139     REST OF THE WORLD BETA RADIATION THERAPY MARKET SHARE, BY ISOTOPES, (2017 V/S 2024) (%)
      • FIGURE 140     REST OF THE WORLD BRACHYTHERAPY MARKET SHARE, BY ISOTOPE, (2017 V/S 2024) (%)
      • FIGURE 141     REST OF THE WORLD NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BY APPLICATION, (2017 V/S 2024) (%)
      • FIGURE 142     REST OF THE WORLD NUCLEAR MEDICINE SHARE, BY END-USER, (2017) (%)
      • FIGURE 143     REST OF THE WORLD NUCLEAR MEDICINE SHARE, BY COUNTRY, (2017 V/S 2024) (%)
      • FIGURE 144     BRAZIL NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2017) ($MN)
      • FIGURE 145     BRAZIL NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 146     BRAZIL PET MARKET REVENUE BY APPLICATION AND THERAPEUTIC MARKET REVENUE BY RADIATION TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 147     BRAZIL NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BY APPLICATION AND NUCLEAR MEDICINE MARKET REVENUE, BY END-USER, (2017 V/S 2024) ($MN)
      • FIGURE 148     REST OF LATAM NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2017) ($MN)
      • FIGURE 149     REST OF LATAM NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 150     REST OF LATAM PET MARKET REVENUE BY APPLICATION AND THERAPEUTIC MARKET REVENUE BY RADIATION TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 151     REST OF LATAM NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE BY APPLICATION AND NUCLEAR MEDICINE MARKET REVENUE BY END-USER, (2017 V/S 2024) ($MN)
      • FIGURE 152     MIDDLE EAST AND SOUTH AFRICA NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY AND DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2017) ($MN)
      • FIGURE 153     MIDDLE EAST AND SOUTH AFRICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2017 V/S 2024) ($MN)
      • FIGURE 154     MIDDLE EAST AND SOUTH AFRICA PET MARKET REVENUE, BY APPLICATION AND THERAPEUTIC MARKET REVENUE BY RADIATION TYPE, (2017 V/S 2024) ($MN)
      • FIGURE 155     MIDDLE EAST AND SOUTH AFRICA NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE BY APPLICATION AND NUCLEAR MEDICINE MARKET REVENUE BY END-USER, (2017 V/S 2024) ($MN)
      • FIGURE 156     KEY GROWTH STRATEGIES (2016 – 2018)
      • FIGURE 157     SWOT: ADVANCE ACCELERATOR APPLICATIONS SA
      • FIGURE 158     SWOT: AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANIZATION
      • FIGURE 159     SWOT: BAYER GROUP
      • FIGURE 160     SWOT: CARDINAL HEALTH, INC.
      • FIGURE 161     SWOT: CURIUM PHARMA
      • FIGURE 162     SWOT: FUJIFILM HOLDING CORPORATION
      • FIGURE 163     SWOT: GE HEALTHCARE
      • FIGURE 164     SWOT: JUBILANT LIFESCIENCE
      • FIGURE 165     SWOT: LANTHEUS MEDICAL IMAGING INC.
      • FIGURE 166     SWOT: SOTERA HEALTH LLC (NORDION INC)
      • FIGURE 167     SWOT: NECSA (NTP RADIOISOTOPES SOC LTD)
      • FIGURE 168     SWOT: SIEMENS AG

      LIST OF COMPANIES

      • 1     13 C Molecular
      • 2     iThemba labs
      • 3     Actinium Pharmaceuticals, Inc
      • 4     Advanced Nuclear Medicine Ingredients
      • 5     Alpha Tau Medical
      • 6     Arronax Cyclotron
      • 7     Australian Nuclear Science and Technology Organization (ANSTO)
      • 8     Bayer Group
      • 9     Becton, Dickinson and Company (Bard Medicals)
      • 10     Beijing Zhibo Biomedical Technology Co. Ltd
      • 11     Best Medical International, Inc
      • 12     Blue Earth Diagnostics Limited
      • 13     Board of Radiation & Isotope Technology
      • 14     Bracco Group
      • 15     BTG International Ltd
      • 16     BV Cyclotron VU
      • 17     Cardinal Health Inc.
      • 18     Cellectar Biosciences
      • 19     Center of Molecular Research
      • 20     Centre for Probe Development and Commercialization
      • 21     China National Nuclear Corporation (China Isotope & Radiation Corporation)
      • 22     Clarity’s Pharmaceuticals
      • 23     Curium Pharma
      • 24     Eckert & Ziegler Strahlen
      • 25     Eczacıbaşı-Monrol Nuclear Products
      • 26     Eli Lilly & Co (Avid Radiopharmaceuticals)
      • 27     Eurisotop
      • 28     Fujifilm Corporation
      • 29     GE Company
      • 30     Huayi Technology Co., Ltd (Huayi Isotopes Co)
      • 31     Institute of Isotopes
      • 32     International Isotopes Inc.
      • 33     IsoAid LLC
      • 34     Iso-Analytical Ltd.
      • 35     Isoflex Isotope
      • 36     Isorad Ltd
      • 37     Isoray Medical Inc
      • 38     IsoSciences, LLC
      • 39     Isotopia Molecular Imaging Ltd.
      • 40     ITM Isotopen Technologien München AG
      • 41     Jubilant Lifescience (Triad Isotopes & Draximage)
      • 42     Lantheus Medical Imaging Inc
      • 43     Linde Group
      • 44     Los Alamos National Laboratory (LANL)
      • 45     Medical Isotopes Inc
      • 46     Merck KGaA (Sigma Aldrich-Isotec Inc)
      • 47     Mitsubishi Chemical Holdings (Tayyo Nippon Sanso Corporation)
      • 48     Navidea Biopharmaceuticals Inc
      • 49     Nihon Medi Physics Co Ltd
      • 50     Novartis International AG (Advanced accelerator Application (AAA) )
      • 51     Nuclear Research and Consultancy Group (NRG)
      • 52     Omicron Biochemicals Inc.
      • 53     Orano Med (Areva Med)
      • 54     Otsuka Pharmaceutical (Cambridge Isotope Laboratories, Inc.)
      • 55     Pars Isotope
      • 56     Perkin Elmer
      • 57     Perma-Fix Environmental Services, Inc. (Perma Fix Medical SA) (Poland)
      • 58     Perma-Fix Medical SA
      • 59     ROTOP Pharmaka GmbH
      • 60     Shangai GMS Pharma
      • 61     Shangai Research Institute of Chemical Industry
      • 62     Shine Medical Technologies, Inc
      • 63     Siemens AG
      • 64     Sofie Biosciences Inc (Zevacor Pharma)
      • 65     Solcom Limited
      • 66     Sotera health, LLC (Nordion Inc)
      • 67     South African Nuclear Energy Corporation (NTP Radioisotopes SOC Ltd)
      • 68     Swan Isotopen AG
      • 69     Teva Pharmaceutical Industries Ltd (Auspex Pharmaceuticals)
      • 70     Theragenics Corporation
      • 71     Theragnostics Ltd
      • 72     Tianjin Seeds Biological Pharmacy Co. Ltd
      • 73     Yantai DongCheng Biochemicals Co. Ltd.